Table 1. Baseline Characteristics of Patients.
| Characteristic | Statin use, No. (%) of patients | P value | |
|---|---|---|---|
| Yes (n = 548) | No (n = 309) | ||
| Demographic characteristics | |||
| Age, mean (SD), y | 62.6 (8.7) | 61.1 (8.7) | .01 |
| Male | 359 (65.5) | 181 (58.6) | .04 |
| BMI, mean (SD) | 25.6 (3.4) | 25.7 (3.3) | .56 |
| CT interval, y | |||
| 2-4 | 362 (66.1) | 223 (72.2) | .15 |
| 4-6 | 141 (25.3) | 62 (20.1) | |
| >6 | 45 (8.2) | 24 (7.8) | |
| Location | |||
| Korea | 376 (68.6) | 245 (79.2) | .22 |
| Canada | 17 (3.1) | 10 (3.2) | |
| Europe | 145 (26.5) | 45 (14.6) | |
| Brazil | 10 (1.8) | 9 (2.9) | |
| Risk factors | |||
| Diabetes | 161 (29.4) | 62 (20.1) | .003 |
| Hypertension | 350 (63.9) | 156 (50.5) | <.001 |
| Family history for CAD | 135 (24.6) | 67 (21.7) | .33 |
| Currently smoking | 100 (18.3) | 54 (17.5) | .78 |
| Medication use at baseline | |||
| Aspirin | 359 (65.5) | 101 (32.7) | <.001 |
| ACE inhibitor or ARB | 230 (42.0) | 79 (25.6) | <.001 |
| β-Blocker | 237 (43.3) | 63 (20.5) | <.001 |
| Lipid profile at baseline | |||
| Cholesterol, mean (SD), mg/dL | |||
| Total | 180 (44) | 186 (35) | .05 |
| LDL | 107 (40) | 113 (29) | .03 |
| HDL | 49 (13) | 50 (13) | .72 |
| Lipid profile at follow-up | |||
| Cholesterol, mean (SD), mg/dL | |||
| Total | 159 (37) | 181 (34) | <.001 |
| LDL | 88 (31) | 110 (30) | <.001 |
| HDL | 49 (13) | 49 (12) | .51 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAD, coronary artery disease; CT, computed tomography; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
SI conversion factors: To convert total cholesterol, LDL, or HDL to millimoles per liter, multiply by 0.0259.